Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl. J. Med. 347, 261–271 (2002).

Article  PubMed  Google Scholar 

Tomelleri, A. et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat. Rev. Rheumatol. 19, 446–459 (2023).

Article  CAS  PubMed  Google Scholar 

Hunder, G. G. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin. Proc. 81, 1071–1083 (2006).

Article  PubMed  Google Scholar 

Hamrin, B., Jonsson, N. & Landberg, T. Arteritis in ‘polymyalgia rheumatica’. Lancet 1, 397–401 (1964).

Article  CAS  PubMed  Google Scholar 

Salvarani, C. et al. Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun. Rev. 23, 103415 (2024).

Article  PubMed  Google Scholar 

Camellino, D., Dejaco, C., Buttgereit, F. & Matteson, E. L. Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis? Rheum. Dis. Clin. North Am. 45, 549–567 (2019).

Article  PubMed  Google Scholar 

Dejaco, C. et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 83, 48–57 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Prieto-González, S. et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open 3, e000570 (2017).

Article  PubMed  PubMed Central  Google Scholar 

van Sleen, Y. et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology 58, 1383–1392 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Dejaco, C. et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann. Rheum. Dis. 70, 447–453 (2011).

Article  PubMed  Google Scholar 

Bolhuis, T. E. et al. Definitions of and instruments for disease activity, remission and relapse in polymyalgia rheumatica: a systematic literature review. Rheumatology 64, 455–469 (2025).

Article  PubMed  Google Scholar 

Dejaco, C. et al. What is a response in randomised controlled trials in giant cell arteritis? Ann. Rheum. Dis. 82, 897–900 (2023).

Article  CAS  PubMed  Google Scholar 

Birkhead, N. C., Wagener, H. P. & Shick, R. M. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J. Am. Med. Assoc. 163, 821–827 (1957).

Article  CAS  PubMed  Google Scholar 

Maz, M. et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. 73, 1349–1365 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Hellmich, B. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheumatic Dis. 79, 19–30 (2020).

Article  Google Scholar 

Labarca, C. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology 55, 347–356 (2016).

Article  PubMed  Google Scholar 

Hayreh, S. S., Zimmerman, B. & Kardon, R. H. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol. Scand. 80, 355–367 (2002).

Article  PubMed  Google Scholar 

Soriano, A. et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat. Rev. Rheumatol. 13, 476–484 (2017).

Article  PubMed  Google Scholar 

Foré, R. et al. BOB-ACG study: pulse methylprednisolone to prevent bilateral ophthalmologic damage in giant cell arteritis. A multicentre retrospective study with propensity score analysis. Jt Bone Spine 91, 105641 (2024).

Article  Google Scholar 

Mazlumzadeh, M. et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 54, 3310–3318 (2006).

Article  CAS  PubMed  Google Scholar 

Chevalet, P. et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J. Rheumatol. 27, 1484–1491 (2000).

CAS  PubMed  Google Scholar 

Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).

Article  CAS  PubMed  Google Scholar 

Samson, M. et al. Methotrexate versus tocilizumab for treatment of giant cell arteritis (METOGiA trial): a multicenter, randomized, controlled trial. Arthritis Rheumatol. 77 (Suppl. 9), abstr. 0891 (2025).

De Silva, M. & Hazleman, B. L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis. 45, 136–138 (1986).

Article  PubMed  PubMed Central  Google Scholar 

Schaufelberger, C., Möllby, H., Uddhammar, A., Bratt, J. & Nordborg, E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol. 35, 327–329 (2006).

Article  CAS  PubMed  Google Scholar 

Doury, P., Pattin, S., Eulry, F. & Thabaut, A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 26, 689–690 (1983).

Article  CAS  PubMed  Google Scholar 

Le Guennec, P. et al. [Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients]. Rev. Rhum. Ed. Fr. 61, 485–490 (1994).

PubMed  Google Scholar 

Kramarič, J., Rotar, Ž, Tomšič, M. & Hočevar, A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: a single-center, open-label study. Front. Med. 9, 1069013 (2022).

Article  Google Scholar 

Quartuccio, L. et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 51, 1677–1686 (2012).

Article  CAS  PubMed  Google Scholar 

Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology 48, 250–253 (2009).

Article  CAS  PubMed  Google Scholar 

Berger, C. T., Wolbers, M., Meyer, P., Daikeler, T. & Hess, C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 48, 258–261 (2009).

Article  CAS  PubMed  Google Scholar 

Nesher, G. et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 50, 1332–1337 (2004).

Article  CAS  PubMed  Google Scholar 

Mollan, S. P., Sharrack, N., Burdon, M. A. & Denniston, A. K. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst. Rev. 2014, CD010453 (2014).

PubMed  PubMed Central  Google Scholar 

Chaddock, N. J. M. et al. Age, anticoagulants, hypertension and cardiovascular genetic traits predict cranial ischaemic complications in patients with giant cell arteritis. Ann. Rheum. Dis. 84, 329–340 (2025).

Article  CAS  PubMed  Google Scholar 

Ciccia, F. et al. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? Lancet Rheumatol. 3, e874–e885 (2021).

Article  CAS